New Drug Info – Ampydin

    • Anonymous
      February 20, 2007 at 8:33 am

      [B]Orphan Drug 4-Aminopyridine (Ampydin) for Chronic Motor and Sensory Deficits of GBS[/B]

      On December 20, the FDA granted orphan drug status for an immediate release, orally administered version of 4-aminopyridine (Ampydin, made by Neurorecovery, Inc) in the treatment of chronic functional motor and sensory deficits resulting from Guillain-Barré syndrome (GBS).

      According to a company news release, 4-aminopyridine is currently on the FDA’s compounding for compassionate use list for treatment of certain neuropathies and for spinal cord injury and multiple sclerosis.

      An international phase 3 trial of the product for the GBS indication is expected to begin in the United States, Canada, and the European Union during the first half of 2007.

      Related Article => [HTML][/HTML]

    • Anonymous
      February 20, 2007 at 5:29 pm

      Thanks for that info Jasper.

    • Anonymous
      February 20, 2007 at 7:11 pm

      Did a Google, found this:


      [QUOTE]What’s new in the world of Research
      updated 17 February, 2006

      This page will contain information on global research into issues of interest to GBS/CIDP patients and their healthcare providers. Older information will be replaced as new information becomes available, so please check often![/QUOTE]

      [COLOR=”Red”]Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine [registration required] [/COLOR]

      [COLOR=”RoyalBlue”]This US study will assess the usefulness and safety of 4-amino-pyridine (4-AP) in patients suffering chronic functional deficits from GBS. 4-AP is a potassium channel blocker that could potentially improve nerve conduction, particularly across partially demyelinated axons. Increasing nerve conduction may improve motor performance as well as decreased fatigue. Over 20% of GBS patients have permanent residual motor deficits that affect their daily life.
      NLM Identifier NCT00056810
      posted here: 05.2003[/COLOR]